Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease

Eligibility Criteria

• * ECOG performance status 0-1 or KPS ≥ 70%
• * Age ≥ 18 years
• * Endometrioid adenocarcinoma histologic diagnosis on endometrial biopsy or dilatation and curettage
• * No evidence of extrauterine disease, or suspicious pelvic lymph nodes, or distant metastases, or cervical invasion on pre-operative conventional imaging studies (Pelvic +/- Abdomen CT or MRI or sonogram, or body PET scan) and physical examination (uterine confined by exam and imaging )
• * Suitable candidate for surgery
• * Planned surgical treatment including hysterectomy in combination with SLN biopsy and a bilateral salpingo-oophorectomy
• * No history of second primary cancer (invasive or in situ) within the past 5 years, not including non-melanoma skin cancer
• * Approved and signed informed consent
• * No history of neoadjuvant chemotherapy or radiotherapy for endometrial cancer
• * No history of prior pelvic or abdominal radiotherapy
• * Extrauterine disease, or gross lymph node involvement, or cervical invasion suspected on pre-operative imaging studies and physical examination (disease not uterine confined clinical stage \> I)
• * Contraindication for SLN mapping
• * The planned treatment is not surgery, or the surgical treatment does not include hysterectomy in combination with SLN biopsy and a bilateral salpingo-oophorectomy
• * At surgery, the patient must undergo:
• * Hysterectomy
• * Bilateral salpingo-oophorectomy, unless already previously performed
• * Bilateral pelvic SLN mapping (bilateral sentinel nodes are negative for malignancy)
• * On the final pathologic report, the patient must have a diagnosis of:
• * Stage I intermediate-risk endometrial endometrioid cancer (Grade 1 or Grade 2 with ≥ 50% myometrial invasion or Grade 3 with \<50% myometrial invasion, including non-invasive disease)
• * Negative pelvic peritoneal cytology
• * Adjuvant treatment as recommended by the multidisciplinary team must be as follows:
• * No adjuvant treatment, or
• * Intravaginal radiation only
• * There is intra-operative detection of extra-uterine disease or grossly involved lymph nodes
• * Presence of any positive pelvic nodes including micrometastasis and isolated tumor cells (ITC)
• * Hysterectomy is not performed
• * Bilateral salpingo-oophorectomy is not performed, unless already previously performed
• * Failed unilateral or bilateral SLN mapping
• * Patient undergoes a complete unilateral or bilateral pelvic lymphadenectomy
• * Patient undergoes a radical type C hysterectomy
• * Stage IA endometrioid cancer Grade1 or 2 and myometrial invasion \<50%
• * Stage IB Grade 3 endometrioid cancer
• * Non-endometrioid histology: Serous, clear cell, carcinosarcoma, undifferentiated, or de-differentiated histology noted on final hysterectomy pathology
• * Empty unilateral or bilateral sentinel lymph nodal packet(s)
• * Positive peritoneal cytology